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PREAMBLE
The Society of Nuclear Medicine and Molecular Imaging
(SNMMI) is an international scientific and professional
organization founded in 1954 to promote the science,
technology and practical application of nuclear medicine.
Its 16,000 members are physicians, technologists, and
scientists specializing in the research and practice of
nuclear medicine. In addition to publishing journals, news-
letters, and books, the SNMMI also sponsors international
meetings and workshops designed to increase the compe-
tencies of nuclear medicine practitioners and to promote
new advances in the science of nuclear medicine. The
European Association of Nuclear Medicine (EANM) is
a professional nonprofit medical association that facilitates
communication worldwide between individuals pursuing
clinical and research excellence in nuclear medicine. The
EANM was founded in 1985.
The SNMMI/EANM will periodically define new guide-
lines for nuclear medicine practice to help advance the sci-
ence of nuclear medicine and to improve the quality of service
to patients. Existing practice guidelines will be reviewed for
revision or renewal as appropriate, on their fifth anniversary
or sooner, if indicated.
Each practice guideline, representing a policy statement
by the SNMMI/EANM, has undergone a thorough consen-
sus process in which it has been subjected to extensive
review. The SNMMI/EANM recognizes that the safe and
effective use of diagnostic nuclear medicine imaging requires
specific training, skills, and techniques, as described in each
document.
The EANM and SNMMI have written and approved these
guidelines to promote the use of nuclear medicine procedures
with high quality. These guidelines are intended to assist
practitioners in providing appropriate nuclear medicine care
for patients. They are not inflexible rules or requirements of
practice and are not intended, nor should they be used, to
establish a legal standard of care. For these reasons and those
set forth below, the SNMMI/EANM cautions against the use
of these guidelines in litigation in which the clinical
decisions of a practitioner are called into question.
The ultimate judgment regarding the propriety of any
specific procedure or course of action must be made by
medical professionals taking into account the unique circum-
stances of each case. Thus, there is no implication that an
approach differing from the guidelines, standing alone, is
below the standard of care. To the contrary, a conscientious
practitioner may responsibly adopt a course of action
different from that set forth in the guidelines when, in the
reasonable judgment of the practitioner, such course of
action is indicated by the condition of the patient, limitations
of available resources, or advances in knowledge or tech-
nology subsequent to publication of the guidelines.
The practice of medicine involves not only the science but
also the art of dealing with the prevention, diagnosis, allevi-
ation, and treatment of disease. The variety and complexity
of human conditions make it impossible to always reach the
most appropriate diagnosis or to predict with certainty a
particular response to treatment. Therefore, it should be
recognized that adherence to these guidelines will not ensure
an accurate diagnosis or a successful outcome. All that should
be expected is that the practitioner will follow a reasonable
course of action based on current knowledge, available
resources, and the needs of the patient to deliver effective
and safe medical care. The sole purpose of these guidelines is
to assist practitioners in achieving this objective.
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I. INTRODUCTION
18F-fluorodeoxyglucose (18F-2-fluoro-2-deoxyglucose or
FDG) positron emission tomography (PET) and PET/CT
are noninvasive diagnostic imaging procedures providing
tomographic images for the determination of localized met-
abolic activity. Fluorine-18 (18F) is a cyclotron-produced
radioisotope with a half-life of 109.7 min that undergoes
positron decay. 18F-FDG is an analog of glucose and is
taken up by living cells via cell membrane glucose trans-
porters and subsequently phosphorylated with hexokinase
inside most cells. 18F-FDG has been proposed for imaging
infection/inflammation in part because it has been seen at
sites of infection/inflammation during routine 18F-FDG im-
aging of cancer patients. Further studies showed that cells
involved in infection and inflammation, especially neutro-
phils and the monocyte/macrophage family, are able to ex-
press high levels of glucose transporters, especially GLUT1
and GLUT3, and hexokinase activity (1–5). From limited
experimental studies, it seems that the ability of the proce-
dure to identify sites of inflammation and infection is related
to the glycolytic activity of the cells involved in the inflam-
matory response. Many types of cells are involved in this
process although no single cell was found specifically and
consistently involved in all models. In addition, enhanced
glucose consumption and subsequent 18F-FDG uptake can
also be the result of a stress reaction of the affected cells
in response to cell damage (metabolic flare) (6).
II. GOALS
The aim of this guideline is to provide general information
about performing 18F-FDG PET or PET/CT in inflammation
and infection. We provide evidence for efficacy where it is
available, but the use of 18F-FDG imaging in inflammation
and infection is rapidly evolving and these guidelines cannot
be seen as definitive. Therefore, the indications mentioned
within this guideline should be regarded as current advice
and areas for clinical research rather than as fully approved
clinical indications. Despite the limited literature available
on the use of 18F-FDG imaging in these indications, it is
clear that the use of metabolic imaging using 18F-FDG, to-
gether with morphologic imaging, that is, PET/CT or fusion
of PET and CT data (further referred to as 18F-FDG imag-
ing), is becoming the scintigraphic method of choice. It can
be expected that after further validation, PET/CT may be-
come a first-line tool in these nononcologic indications.
This guideline complements the EANM and SNMMI
guidelines for the use of 18F-FDG PET for tumor imaging
(7,8) and, to avoid duplication, will not reproduce any
statements that overlap. These include information con-
cerning PET or PET/CT camera performance and quality
control, general acquisition parameters, radiopharmaceuti-
cal acceptance, and general basic and clinical aspects of
18F-FDG imaging that may apply to both tumor and infec-
tion/inflammation imaging. The present guideline aims to
provide the user with basic knowledge of and competence
in the use of 18F-FDG imaging in the field of inflammatory
and infectious disorders.
III. DEFINITIONS
This section is not applicable.
IV. COMMON CLINICAL INDICATIONS
No appropriateness criteria have been developed to date
for this procedure. The development of 18F-FDG in this
field is rapidly evolving, especially since the emergence
of PET/CT. Table 1 summarizes the indications that have
been reported in the literature with various success rates.
The list is based on an evaluation of scientific peer-
reviewed publications (at least with an abstract in English
allowing the evaluation of the study) from 1994 to Decem-
ber 2011. Only original publications with more than 10
patients and with the possibility of calculating the diagnos-
tic sensitivity, specificity, and accuracy were taken into
consideration.
Although there is still insufficient literature for this to be
described as an evidence-based indication, we can conclude,
on the basis of a cumulated reported accuracy (.85%) and
expert opinion that major indications for 18F-FDG PET/CT
in infection and inflammation are as follows:
• Sarcoidosis (9–15).
• Peripheral bone osteomyelitis (nonpostoperative, non–
diabetic foot) (16–23).
• Suspected spinal infection (spondylodiskitis or verte-
bral osteomyelitis, nonpostoperative) (24–28).
TABLE 1
Published Studies with More Than 10 Patients Before December 2011
Disease Considered papers Sensitivity Specificity Accuracy References
Sarcoidosis 7 (173 patients) 93.5% (7 papers) Data not available 95.5% (1 papers) 9–15
Osteomyelitis 8 (287 patients) 94.6% (8 papers) 91.5% (8 papers) 94.5% (6 papers) 16–23
Spondylodiskitis 5 (136 patients) 100.0% (5 papers) 89.3% (5 papers) 91.0% (4 papers) 24–28
FUO 15 (758 patients) 90.6% (15 papers) 76.9% (15 papers) 86.4% (10 papers) 29–44
Vasculitides 12 (283 patients) 80.4% (12 papers) 89.3% (12 papers) 85.0% (3 papers) 45–56
Diabetic foot 5 (220 patients) 70.6% (5 papers) 84.4% (5 papers) 80.0% (5 papers) 88–92
Prosthesis (knee 1 hip) 17 (770 patients) 95.0% (17 papers) 98.0% (17 papers) 78.0% (8 papers) 93–109
Vascular grafts 5 (189 patients) 88.9% (5 papers) 64.6% (4 papers) 74.5% (4 papers) 110–114
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• Evaluation of fever of unknown origin (FUO) (29–44),
including true FUO (defined according to the criteria of
Durack and Street (44)), postoperative fever and recurrent
sepsis, immunodeficiency (both induced and acquired)-
related FUO, neutropenic fever, and isolated acute-phase
inflammation markers (persistently raised C-reactive pro-
tein and/or erythrocyte sedimentation rate).
• Evaluation of metastatic infection and of high-risk
patients with bacteremia (32).
• Primary evaluation of vasculitides (e.g., giant cell ar-
teritis) (45–56).
Other well-described applications, but without sufficient
evidence-based indication, include the following:
• Evaluation of potentially infected liver and kidney
cysts in polycystic disease (56–63).
• Suspected infection of intravascular devices, pace-
makers, and catheters (64–71).
• AIDS-associated opportunistic infections, associated
tumors, and Castleman disease (72–83).
• Assessment of metabolic activity in tuberculosis
lesions (84–87).
Considering the available published data, it is unclear if
18F-FDG imaging offers any significant advantage over
radiolabeled white blood cells or antigranulocyte monoclo-
nal antibodies in the following situations:
• Diabetic foot infections (88–92).
• Joint prosthetic infections (93–109).
• Vascular prosthetic infections (110–114).
• Inflammatory bowel diseases (115,116).
• Endocarditis (117–119).
It must be emphasized that large prospective studies
comparing different nuclear medicine procedures are often
lacking. Nevertheless, the level of evidence available at this
time for many of these indications remains insufficient to
strongly advise the use of 18F-FDG imaging as a first-line
diagnostic tool. The level of evidence is at best at Cochrane
grade B, especially for true FUO, spinal infection, and vas-
culitis. The level of evidence is lower (Cochrane C or D) for
other indications. It must be kept in mind that the choice
between 18F-FDG imaging and an alternative technique may
depend on the need for rapid diagnosis and local availability
of equipment and labeled agents. For example, some specific
indications such as the evaluation of vascular prostheses and
the diabetic foot absolutely require the use of hybrid PET/CT
for precise anatomic localization of the 18F-FDG uptake.
V. REGULATORY ISSUES
There is consistent progress in the field, with regular new
literature and registration of 18F-FDG for several indica-
tions by the European Medicines Agency. In the United
States 18F-FDG is not approved by the Food and Drug
Administration for indications other than oncology, cardi-
ology, and epilepsy (120).
VI. QUALIFICATIONS AND RESPONSIBILITIES
OF PERSONNEL
In the United States, see the SNMMI Guideline for
General Imaging and the SNMMI Guideline for Tumor
Imaging with 18F-FDG PET/CT (8). In Europe, the certified
nuclear medicine physician who performed the study and
signed the report is responsible for the procedure, according
to national laws and rules.
VII. PROCEDURE/SPECIFICATIONS OF
THE EXAMINATION
A. Request
The request for the examination should include suf-
ficient medical information to demonstrate medical ne-
cessity and should include the diagnosis, pertinent history,
and questions to be answered. The medical record should
be reviewed. Relevant laboratory tests should be consid-
ered. When available, the results of prior imaging studies
should be reviewed, including plain-film radiography, CT,
MRI, bone scanning, and 18F-FDG PET/CT. Relevant
prior studies should be directly compared with current
imaging findings when possible.
B. Patient preparation and precautions
The major goals of preparation are to minimize
tracer uptake in normal tissues, such as the myocar-
dium, skeletal muscle, and urinary tract, while main-
taining uptake in target tissues.
1. Pregnancy (suspected or confirmed)
In the case of a diagnostic procedure in a patient
who is known or suspected to be pregnant, a clinical
decision is necessary to consider the benefits
against the possible harm of performing any pro-
cedure. The International Committee for Radiation
Protection (ICRP) reports that the administration of
259 MBq (7 mCi) of 18F-FDG results in an
absorbed radiation dose of 4.7 mGy to the nongra-
vid uterus (i.e., 1.8 · 1022 mGy/MBq) (121). Di-
rect measurements of 18F-FDG uptake in a case
study suggested higher doses to the fetus than cur-
rently provided in standard models (122). A preg-
nancy test may help with the decision, provided the
10-d postovulation blackout is understood. In case
of doubt and in the absence of any emergency, the
10-d rule should be adopted.
2. Breastfeeding
The ICRP does not recommend interruption of
breast feeding after 18F-FDG administration since
little 18F-FDG is excreted in the milk (121). How-
ever, the suggestion may be made that contact be-
tween mother and child be limited for 12 h after
injection of 18F-FDG to reduce the radiation dose
that the infant receives from external exposure from
the mother. It is recommended that the infant be
breastfed just before injection, to maximize the
time between the injection and the next feeding.
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3. Diabetes and serum glucose level before 18F-FDG
administration
It has been advocated that high serum glucose lev-
els may interfere with the targeting of inflammatory
and infectious sites because of competitive inhibition
of 18F-FDG uptake by D-glucose. After sporadic re-
ports of patients with glucose levels higher than 2 g/L
(10 mmol/L) who were studied successfully, it has
recently been demonstrated (in a series including
123 patients with suspected infection) that neither di-
abetes nor hyperglycemia at the time of the study had
any significant impact on the false-negative rate in
this clinical scenario (123). This is different from
tumor imaging, especially of pancreatic and lung can-
cers, for which reduced 18F-FDG uptake has been
observed at 1.4 g/L (8 mmol/L) (124). Although
efforts should be made to decrease blood glucose to
the lowest possible level, if the study is normally in-
dicated in those with unstable (“brittle”) or poorly
controlled diabetes (often associated with infection),
hyperglycemia should not represent an absolute con-
traindication for performing the study. Therefore we
recommend the same advice and suggest registering
blood glucose level and any other information that
could be relevant for scan interpretation.
4. Kidney failure
18F-FDG imaging can be performed in patients
with kidney failure, although the image quality may be
suboptimal and prone to interpretation pitfalls (125).
5. Instructions to patients
The technologist, nurse, or physician should give the
patient a thorough explanation of the test. Patients must
fast (although intake of noncaloric beverages, such as
water or coffee, is allowed) for at least 4 h before
18F-FDG imaging, during which time they should be
encouraged to drink sufficient water to ensure hydra-
tion and promote diuresis (7). In specific situations
(e.g., endocarditis), a longer fast is recommended to
optimize the reduction of myocardial uptake.
Necessary medications are allowed and must be
recorded. Ideally, the scan may be scheduled 3–4 h
after breakfast in diabetic patients who have received
their insulin early in the morning (e.g., 7:00 AM).
Diabetic patients should take their medications early
in the morning, and the 18F-FDG imaging should be
scheduled for late morning. Detailed instructions can
be found in the EANM guidelines for tumor imaging.
It is strongly advised that commencement of steroid
treatment be avoided between the request date for the
study and the appointment. The use of steroid treat-
ment could result in a false-negative result, especially
in giant cell arteritis and other systemic vasculitides
(126). Because the effect of antibiotics on 18F-FDG
uptake is unknown, it is important to be aware of
ongoing antibiotic treatment, but no general recom-
mendation on withdrawal can be stated.
The patient should be advised to avoid strenuous
physical exercise within 24 h before injection.
Patients should void before being positioned on
the PET/CT table.
6. Preinjection clinical evaluation by the nuclear med-
icine physician
18F-FDG imaging recently showed high perfor-
mance in critically ill patients with suspected in-
fection (41). The management of such patients is,
however, time consuming and technically challeng-
ing, requiring high-level multidisciplinary skills. If
18F-FDG imaging is scheduled in such a patient,
issues concerning logistics, nursing care, and medi-
cal care should be anticipated and reviewed carefully.
The nuclear medicine physician should have
available and take into account all information that
could facilitate the interpretation of 18F-FDG imag-
ing (CT, MRI, and other previously performed di-
agnostic imaging, including any previous PET
study). In particular, the following parameters
should be checked:
• Fasting state (except in some diabetics who re-
ceived insulin, see “Instructions to Patients:
Medications”).
• History of diabetes.
• Patient weight and height (weight should be mea-
sured in very ill patients if feasible and if stan-
dardized uptake values [SUVs], are needed).
• Fever or elevation of acute inflammatory markers
such as erythrocyte sedimentation rate or C-reactive
protein.
• Trauma, recent surgery, or recent invasive diag-
nostic procedures (at least within the last 4 wk).
• History of a neoplastic disorder, recent chemo-
therapy (many patients with previously known
cancer or under treatment for cancer may be can-
didates for 18F-FDG imaging for nonmalignant
indications), or radiation therapy (at least within
the last 3 mo); bone marrow, spleen, and gastro-
intestinal biodistribution of 18F-FDG may vary.
• Presence of a known infectious or inflammatory
condition or immunosuppressive status.
• Pathophysiologic disturbances and symptoms,
such as diarrhea and localized pain, especially
in the extremities (e.g., knee, for appropriate
choice of field of view).
• Presence of benign disease with high tissue pro-
liferation.
• Pregnancy or suspected pregnancy, breastfeed-
ing, and date of the last menses.
• Blood glucose level.
7. Patient relaxation.
Before 18F-FDG administration, the patient should
relax in a waiting room to minimize muscular activ-
ity and thereby physiologic uptake of 18F-FDG in
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muscles. The waiting room should be at an ade-
quate temperature (20C–22C), and drafts should
be prevented in order to reduce uptake in brown fat.
In selected cases, prevention of brown fat uptake
may be enhanced by the use of b-blocking agents.
Hyperventilation may cause uptake in the dia-
phragm, and stress-induced tension may result in
increased 18F-FDG uptake in the trapezius and para-
spinal muscles. Some authors have proposed admin-
istration of benzodiazepines to obtain muscle
relaxation: this should be restricted to very active
patients and those in whom evaluation of the neck
is essential. If benzodiazepines are given, it is wise
to ensure first that the patient will not drive or un-
dertake activity that requires the patient to be alert
after the procedure. Patients should avoid talking or
chewing immediately before and after 18F-FDG ad-
ministration to minimize 18F-FDG uptake in laryn-
geal and masticatory muscles.
Some of the measures mentioned above may be
superfluous for small-field-of-view acquisitions,
such as a limited acquisition for the evaluation of
a localized infection.
C. Radiopharmaceutical
1. 18F-FDG administered activity in Europe
The injected activity of 18F-FDG to obtain good
imaging with a PET scanner operated in 3-dimen-
sional mode is in the range of 2.5–5.0 MBq/kg, that
is, 175–350 MBq or 4.7–9.5 mCi in a 70-kg stan-
dard adult, although the required dose may depend
on the imaging device and the acquisition time used
(6). Activities should be reduced for infants and
children according to the EANM pediatric dosage
card issued in 2008 (127,128) (www.eanm.org/
docs/dosagecard.pdf). Higher injected activities
may be required in overweight and obese patients.
National limits may be less than these figures, in
which case the relevant national limit should be
applied. 18F-FDG should be administered intrave-
nously, using a minimum 21-gauge indwelling
catheter (or Abbott butterfly) to ensure good venous
access.
2. 18F-FDG administered activity in the United States
The 18F-FDG administered activity should be
370–740 MBq (10–20 mCi) for adults and 3.7–
5.2 MBq/kg (0.10–0.14 mCi/kg) for children. Ad-
ministered activity for children should be based on
body weight and should be as low as reasonably
achievable for diagnostic imaging. For more spe-
cific guidance on pediatric dosing, please refer
to “Pediatric Radiopharmaceutical Administered
Doses: 2010 North American Consensus Guide-
lines” (129).
When feasible, the radiopharmaceutical should
be injected intravenously at a site contralateral to
sites of known or suspected disease. With PET/CT,
the radiation dose to the patient is the combination
of the dose from the PET radiopharmaceutical and
the dose from the CT portion of the study. Lower
administered activities, however, may be appropri-
ate with advancements in PET/CT technology.
3. Uptake period after injection
After administration of 18F-FDG, the patient
should remain quiet until the start of image ac-
quisition and void the urinary bladder as often as
possible to limit radiation to the urinary tract.
A minimum 60-min interval between 18F-FDG in-
jection and acquisition is recommended to obtain
adequate 18F-FDG biodistribution. During this
time, the patient should drink at least 1 L of water
or receive this amount intravenously to promote
diuresis, if there are no contraindications. Patients
should void immediately before image acquisition
begins.
4. Postprocedure recommendations
No other recommendations (other than normal
radiation protection advice) are to be made after
the imaging is finished and the technical quality
of the study has been checked. The patient is free
to resume normal activities without further precau-
tions, except when benzodiazepines or other de-
pressant medications were administered or if the
patient is actively breastfeeding (see “Patient Prep-
aration and Precautions”). Patients who ask about
the report should be informed that a detailed report
will be produced after thorough evaluation of the
18F-FDG study and all available information.
5. Radiation dosimetry
The organ that receives the highest radiation dose
is the urinary bladder. High absorbed doses are
expected in the lactating breast, but figures are
not available from the literature. The effective dose
is 1.9 1022 mSv/MBq for the PET examination
(ICRP 106 (121)) in addition to CT dose, which
may vary according to the type of study performed.
D. Image acquisition
It is not the aim of this guideline to discuss the per-
formance of current PET/CT scanners. Reference is
made to the 2009 EANM guideline for FDG PET and
PET/CT for tumor imaging (7) and the SNMMI Guide-
line for Tumor Imaging with 18F-FDG PET/CT (8).
With current PET/CT scanners, the acquisition is
performed in whole-body mode, using steps of 1.5–
3 min per bed position. Whole-body acquisition is
usually defined as a field of view covering the head
to mid thigh, starting in the pelvic area, when the
bladder is empty. This field of view may not be suffi-
cient in patients with FUO, in whom continuation of
the scan down to the feet may be useful, depending on
the clinical suspicion.
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Conversely, a limited field of view may be used,
with imaging confined only to the region of the clinical
problem (e.g., a hip prosthesis, an infected vascular
graft, or a diabetic foot).
Although dynamic scanning has been described in
orthopedic indications, it has not proven widely useful
and hence is not advised at present in clinical practice.
This applies also to dual-time-point early and late
imaging protocols. From the available literature, dual-
time-point imaging does not reliably help in differen-
tiating infection from cancer.
CT acquisition parameters are detailed in the
EANM and SNMMI tumor imaging guidelines. For
PET/CT, low-dose CT should be performed for atten-
uation correction and anatomic localization.
For diagnostic CT, acquisition parameters should be
determined according to specific radiologic society
guidelines. Injection of iodinated contrast may be in-
dicated to obtain a full PET/CT scan with a diagnostic
CT sequence. However, there are not enough data to
support the use of intravenous contrast in the clinical
setting of infection/inflammation imaging. The use of
contrast is probably indicated in FUO, postoperative
fever, and vascular prostheses but not in vasculitis and
orthopedic infection. In cases of contrast-enhanced
CT, a low-dose CT scan before contrast injection
should be obtained for attenuation correction. An al-
ternative to acquiring 2 CT scans could be to apply
contrast compensation when considering Hounsfield
units.
E. Image analysis and interpretation
1. Physiologic 18F-FDG distribution
Accumulation of 18F-FDG can normally be seen
in the brain, heart, kidneys, and urinary tract at
60 min after injection. The brain has a high uptake
of 18F-FDG (7% of injected activity). The myocar-
dium in a typical fasting state primarily uses free
fatty acids but after a glucose load uses glucose. In
the fasting state, 18F-FDG uptake in the myocar-
dium should be low, but this is variable. Unlike
glucose, 18F-FDG is excreted by the kidneys into
the urine and accumulates in the urinary tract. 18F-
FDG may also be seen in muscles, depending on
recent motor activity and insulin. Uptake in the
gastrointestinal tract varies from patient to patient
and may be increased in patients taking metformin
(130). Uptake is common in the lymphoid tissue of
the Waldeyer ring and in the lymphoid tissue of the
terminal ileum and cecum (131,132). Physiologic
thymic uptake may be present, especially in chil-
dren and young adults (133). Uptake in brown fat
may be observed mainly in young patients and
when the ambient temperature is low. No physio-
logic uptake is noted in the bone itself (unless free
18F-fluoride is present as a contaminant), but espe-
cially in infected or inflamed patients, bone marrow
uptake can be noted to a variable level. This is also
true in patients with hematopoietic regeneration,
such as after chemotherapy, either spontaneously
or after administration of hematopoietic growth factors
(e.g., granulocyte–macrophage colony-stimulating
factor) (134).
2. Qualitative analysis
PET images are visually analyzed by looking for
increased 18F-FDG uptake, taking into consider-
ation the pattern (focal, linear, diffuse), intensity,
and relationship to areas of physiologic distribu-
tion. PET information is compared with morpho-
logic information obtained by CT. It must be kept
in mind that the sensitivity of 18F-FDG for infection
is not absolute and that even in the case of negative
PET results, a thorough interpretation of the CT
scan is essential.
3. Quantitative analysis (SUV)
In contrast to its use in oncology, SUV has not
been validated in inflammation and infection.
Therefore, SUV in this field should be used with
caution in clinical practice. In a single study,
though, in spondylodiskitis, an SUV cutoff greater
than 3 has been suggested to avoid false-positive
findings (26). This criterion, however, cannot be
applied for other diseases. Maximum SUV data
were also analyzed for sarcoidosis (27). Although
correlations were found with other parameters
of disease activity, no real cutoff was derived for
interpretation.
4. General interpretation criteria
To evaluate 18F-FDG imaging, the following
should be taken into consideration:
• Clinical question raised in the request for 18F-
FDG imaging.
• Clinical history.
• Scanning protocol (with or without attenuation
correction).
• Physiologic distribution of 18F-FDG, and its indi-
vidual variations in the specific patient evaluated.
• Localization of the abnormal uptake according to
anatomic imaging data.
• Intensity of 18F-FDG uptake (e.g., maximum
SUV and/or peak SUV).
• Correlation with data from previous clinical, bio-
chemical, and morphologic examinations.
• Presence of potential causes of false-negative
results (lesion size, low metabolic rate, hypergly-
cemia, lesions masked by adjacent high physio-
logic uptake, concomitant drug use interfering
with uptake, such as ongoing steroid therapy in
systemic disorders).
• Presence of potential causes of false-positive re-
sults (injection artifacts and external contamina-
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tion, reconstruction artifacts from attenuation cor-
rection, normal physiologic uptake, pathologic up-
take not related to infection or inflammation).
Care should be taken in the interpretation of PET data
corrected for attenuation using a low-dose CT scan
(particularly when metallic material or implants are pres-
ent). Assessment of both attenuation-corrected and non–
attenuation-corrected images is recommended.
5. Interpretation criteria for specific disorders
There are no general criteria published for all
inflammatory and infectious disorders. Most re-
search articles on the subject have defined interpre-
tation criteria for the purposes of the study. Some
authors have reported specific interpretation criteria
that can be used, although no definitive consensus
has been agreed on.
• Joint prostheses: some interpreting criteria have
been proposed by Reinhartz et al. (106) for painful
hip arthroplasties. The use of their criteria results
in overall accuracy of 95% but has not been con-
firmed by others. Visual interpretation using these
criteria may be more reliable than quantitative
(SUV) analysis, which is not recommended.
• Sarcoidosis: sarcoidosis can mimic malignancies
and especially lymphoma. Keijsers et al., how-
ever, reported that a high parenchymal lung up-
take (with elevated SUV) was predictive of severe
disease activity, especially if the mediastinum and
hilum maximum SUV was low (135). Conversely,
the same authors reported that the absence of met-
abolic activity in the lung parenchyma was related
to low-activity disease and justifies a wait-and-see
policy (136).
• Vascular prostheses: because physiologic uptake
is often visible in vascular prostheses, patterns
of interpretation have been discussed. It is now
felt that linear, diffuse, and homogeneous up-
take is not likely to represent infection whereas
focal or heterogeneous uptake with projection
over the vessel on CT is highly suggestive of
infection (111).
• Vasculitis: Hautzel et al. (137) and Meller et al.
(138) both proposed criteria for the diagnosis of
active giant cell arteritis. The criteria of Meller et
al. are based on visual comparison of uptake in
the aorta with that in the liver or brain but have
not been used or reproduced by others. Using
receiver-operating-characteristic curve analysis,
Hautzel et al. defined an optimal cutoff of 1.0
for aorta-to-liver ratio to differentiate patients
with giant cell arteritis from healthy patients.
Although this cutoff resulted in good diagnostic
performance, this parameter has also not been
further evaluated by other authors.
VIII. DOCUMENTATION/REPORTING
A. Direct communication
Significant abnormalities should be verbally commu-
nicated to the appropriate health care provider if a delay
in treatment might result in significant morbidity. An
example of such an abnormality would be a lesion with
a high risk of pathologic fracture. Other clinically signif-
icant unexpected findings should also be communicated
verbally.
Reporting of abnormalities requiring urgent attention
should be consistent with the policy of the interpreting
physician’s local organization. Written documentation of
verbal reporting should be made in the medical record,
usually as part of the PET/CT report.
B. Contents of the written report
1. Study identification
The report should include the full name of the
patient, medical record number, and date of birth.
The name of the examination should also be in-
cluded, with the date and time it is performed.
The electronic medical record should provide these
data, as well as a unique study number.
2. Clinical information
At a minimum, the clinical history should in-
clude the reason for referral and the specific ques-
tion to be answered. If known, the diagnosis and
a brief treatment history should be provided. The
results of relevant diagnostic tests and prior imag-
ing findings should be summarized.
The type and date of comparison studies should
be stated. If no comparison studies are available,
a statement should be made to that effect.
3. Procedure description
Study-specific information should include the
name of the radiopharmaceutical, the dose in mega-
becquerels or millicuries, the route of administration
(intravenous), and the date and time of administra-
tion. The site of administration is optional. The name,
dose, and route of administration of regulated non-
radioactive drugs and agents should also be stated.
The type of camera should be specified, but specific
equipment information is optional.
A description of the procedure should include the
time the patient was scanned or the time interval
between administration of 18F and the start time of
the scan. The part of the body that is scanned
should be described from the starting to the ending
point. The position of the patient (supine or prone),
and the position of the arms (elevated or by the
sides) should be stated if nonstandard.
Description of the CT part of the examination may
be limited to a statement that a low-mAs CT was
performed for attenuation correction and anatomic
registration of the emission images. However, find-
ings should be reported. If CT was optimized for
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diagnosis, then a more complete description of the
CT protocol and anatomic findings should be pro-
vided.
Routine processing parameters are usually not
stated in the report, but any special circumstances
requiring additional processing, such as motion cor-
rection, should be described.
4. Description of the findings
Significant findings should be described in a log-
ical manner. Findings may be grouped by signifi-
cance or described by body region. An integrated
PET/CT report is preferred, although CT optimized
for diagnosis may be reported separately. For im-
portant 18F-FDG findings, the location, extent, and
intensity of abnormal uptake should be described,
as well as the relevant morphologic CT findings at
the site of 18F-FDG abnormalities. SUV may be
used as a purely descriptive means of reporting,
but the measurement should not be used to render
a specific diagnosis. The integrated PET/CT report
should include any detected incidental findings on
the CT scan that are relevant to patient care.
Limitations should be addressed. Where appropri-
ate, factors that can limit the sensitivity and speci-
ficity of the examination should be identified. In
patients with known cancer evaluated for an episode
of pyrexia, the interpretation should try to separate
uptake within a site of cancer from uptake in a site of
inflammation or infection. Possible sources of error
include a small lesion, a low-grade infection, phys-
iologic uptake around or along exogenous material
(i.e., a foreign body aseptic reaction, such as that
associated with a vascular graft), artifacts (in partic-
ular, those related to overcorrection of attenuation
after contrast injection or due to metallic implants,
devices, and prosthesis), physiologic uptake of 18F-
FDG (in brain; myocardium and other muscles;
brown fat; urinary, gastrointestinal, and oropharyn-
geal tracts; thymus), uptake in known or unknown
malignant disease, treatment-related uptake (after
chemotherapy and radiation therapy and in healing
surgical wounds up to 8 wk, scars, stoma, and tube
placements), and aseptic inflammatory reactive 18F-
FDG uptake (lymph node uptake in sterile arthritis
such as rheumatoid arthritis, reactive lymph nodes in
HIV-positive patients, and following immunization;
atherosclerotic plaques, bone fractures, granulation
tissue).
5. Impression
The most probable diagnosis should be given
whenever possible. A differential diagnosis should
be given when appropriate. When appropriate, fol-
low-up and additional diagnostic studies should be
recommended to clarify or confirm the impression.
C. Issues requiring further clarification
Controversy still remains on the role of 18F-FDG in
infection and inflammation in the presence of artifacts
caused by metallic implants and prostheses and the
added value of SUV in improving the diagnostic accu-
racy of reporting. Strategies for differentiating infection
from sterile inflammation need to be developed. The
utility of 18F-FDG in monitoring response to antibacte-
rial or antiinflammatory therapy is not known.
IX. EQUIPMENT SPECIFICATION
See SNMMI Guideline for Tumor Imaging with 18F-
FDG PET/CT.
X. QUALITY CONTROL AND IMPROVEMENT; SAFETY,
INFECTION CONTROL, AND PATIENT
EDUCATION CONCERNS
Policies and procedures related to quality, patient
education, infection control, and safety should be devel-
oped and implemented in accordance with national rules in
Europe and with the SNMMI policies on quality control,
and patient education in the United States, where appropriate.
In all patients, the lowest exposure factors should be
chosen that will produce images of diagnostic quality.
Equipment performance monitoring should be in accor-
dance with “ACR Technical Standard for Medical Nuclear
Physics Performance Monitoring of PET/CT Imaging
Equipment” in the United States and in accordance with
national rules in Europe.
See also “FDG PET and PET/CT: EANM Procedure
Guidelines for Tumour PET Imaging: version 1.0,” the
SNMMI Guideline for General Imaging, the SNMMI Guide-
line for Use of Radiopharmaceuticals, and the SNMMI
TABLE 2
Radiation Dosimetry for Adults (121)
Administered activity
(intravenously)
Bladder (organ receiving
largest radiation dose)* Effective dose
Radiopharmaceutical MBq mCi mGy/MBq rad/mCi mSv/MBq rem/mCi
18F-FDG 370–740 10–20 0.13 0.48 0.019 0.070
*Voiding interval, 3.5 h. Changes in bladder wall dose are approximately linear with changes in voiding interval; therefore, for voiding
interval of 2.0 h, dose to bladder wall would change by factor of 2/3.5.
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Guideline for Tumor Imaging with 18F-FDG PET/CT for
equipment performance guidelines and quality control.
XI. RADIATION SAFETY IN IMAGING
See the SNMMI Guideline for General Imaging, “FDG
PET and PET/CT: EANM Procedure Guidelines for Tu-
mour PET Imaging: version 1.0,” and Tables 2 and 3.
A. The pregnant or potentially pregnant patient
(Table 4)
The ICRP reports that the administration of 259 MBq
(7 mCi) of 18F-FDG results in an absorbed radiation dose
of 4.7 mGy to the nongravid uterus (i.e., 1.8 · 1022
mGy/MBq) (121). Direct measurements of 18F-FDG up-
take in 1 case study suggested somewhat higher doses
than currently provided in standard models (120). More
detailed information, including information on changes
with the stage of gestation, has been previously reported
(130,131).
B. The breastfeeding patient
The ICRP does not recommend interruption of
breastfeeding after 18F-FDG administration since little 18F-
FDG is excreted in the milk (121). However, the suggestion
may be made that contact between mother and child be
limited for 12 h after injection of 18F-FDG to reduce the
radiation dose the infant receives from external exposure
to breast uptake in the mother. It is recommended that the
infant be breastfed just before injection, to maximize the
time between the injection and the next feeding. Milk
pumped from the breast may also be fed to the infant via
a bottle to avoid close contact with 18F decay in breast tissue.
C. Issues related to the CT radiation dose
from PET/CT
With PET/CT, the radiation dose to the patient is the
combination of the radiation dose from the PET radiophar-
maceutical and the radiation dose from the CT portion of
the study. Radiation dose in diagnostic CT has attracted
considerable attention in recent years, in particular for
pediatric examinations. It can be misleading to quote
a “representative” dose for a CT scan because of the wide
diversity of applications, protocols, and CT systems. This
also applies to the CT component of a PET/CT study. For
example, a body scan may include protocols to reduce the
radiation dose to the patient or to optimize the CT for
diagnostic purposes. The effective dose could range from
approximately 5 to 80 mSv (0.5–8.0 rem) for these op-
tions. It is therefore advisable to estimate the CT dose
specific to the CT system and protocol.
Pediatric and adolescent patients should have their CT
examinations adjusted for patient size, since radiation
dose to the patient increases significantly as the diameter
of the patient decreases.
The effective dose for whole-body CT performed for
attenuation correction and registration of emission
images is in the range of 3.2 mSv (0.32 rem), using the
following parameters: voltage of 120 kV, current of 30
mAs, rotation of 0.5 s, and pitch of 1. In all cases, adaptive
CT dose tools (as now proposed by most manufacturers)
are recommended to reduce the radiation exposure, espe-
cially in young patients.
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